Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The mutant TP53 peptide-HLA class I complex is a tumor-specific neoantigen presented on the surface of cancer cells. TP53 is the most frequently mutated tumor suppressor gene in human cancers, with missense mutations clustering in the DNA-binding domain (such as the R175H hotspot mutation). Intracellular mutant p53 proteins undergo proteasomal degradation, and the resulting mutant peptides (e.g., HMTEVVRHC from p53 R175H) are transported to the endoplasmic reticulum, loaded onto major histocompatibility complex (MHC) class I molecules (such as HLA-A*02:01), and presented on the cell surface. This complex serves as a highly specific target for cancer immunotherapy, distinguishing malignant cells from healthy cells that present wild-type p53 peptides.
Because mutant p53 is an intracellular protein, it is inaccessible to conventional monoclonal antibodies. However, the presentation of mutant p53 peptides by HLA class I molecules allows the targeting of these intracellular mutations via T-cell receptor (TCR)-engineered T-cell therapies (TCR-T) or TCR-mimic (TCRm) bispecific antibodies. Therapeutic agents under development, such as the bispecific T-cell engager CLSP-1025 and the TCR-T cell therapy NT-175, specifically bind to the mutant p53 peptide-HLA complex to redirect and activate cytotoxic T lymphocytes to lyse tumor cells. Major challenges in targeting this complex include its extremely low density on the cancer cell surface, potential cross-reactivity with wild-type p53, and the restriction of therapies to patients with specific HLA haplotypes.
Drugs targeting this complex act by binding specifically to the mutant p53 peptide-HLA class I complex on the tumor cell surface, while ignoring wild-type p53 complexes. Bispecific T-cell engagers (TCEs) or TCR-mimic antibodies simultaneously bind to CD3 on T cells, thereby redirecting and activating cytotoxic T lymphocytes to lyse the tumor cells. Alternatively, TCR-engineered T-cell therapies (TCR-T) utilize genetically modified T cells expressing TCRs specific to this complex to recognize and destroy the cancer cells.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mutant tumor protein p53 peptide-HLA class I complex (mutant p53-HLA-I).